Access the full text.
Sign up today, get DeepDyve free for 14 days.
Arnold Ratner, D. Waldorf, E. Scott (1968)
Alterations of lesions of mycosis fungoides lymphoma by direct imposition of delayed hypersensitivity reactionsCancer, 21
R. Ohno, K. Kimura (1986)
Treatment of multiple myeloma with recombinant interferon alfa‐2aCancer, 57
Bunn Pa, S. Lamberg (1979)
Report of the Committee on Staging and Classification of Cutaneous T-Cell Lymphomas.Cancer treatment reports, 63 4
G. Depanfilis, G. Manara, C. Ferrari, G. Manfredi, F. Allegra (1983)
Imbalance in phenotypic expression of T cell subpopulations during different evolutional stages of lichen planus lesions.Acta dermato-venereologica, 63 5
E. Borden (1979)
Interferons: rationale for clinical trials in neoplastic disease.Annals of internal medicine, 91 3
M. Turbitt, R. MacKie (1986)
An assessment of the diagnostic value of the monoclonal antibodies Leu 8, OKT9, OKT10 and Ki67 in cutaneous lymphocytic infiltratesBritish Journal of Dermatology, 115
H. Ozer, M. Gavigan, J. O'Malley, D. Thompson, B. Dadey, A. Nussbaum-Blumenson, C. Snider, S. Rudnick, R. Ferraresi, S. Norred (1983)
Immunomodulation by recombinant interferon-alpha 2 in a phase I trial in patients with lymphoproliferative malignancies.Journal of biological response modifiers, 2 6
K. Foon, S. Sherwin, P. Abrams, D. Longo, M. Fer, H. Stevenson, J. Ochs, G. Bottino, C. Schoenberger, J. Zeffren (1984)
Treatment of advanced non-Hodgkin's lymphoma with recombinant leukocyte A interferon.The New England journal of medicine, 311 18
E. Vonderheid, E. Tan, E. Sobel, E. Schwab, B. Micaily, B. Jegasothy (1987)
Clinical implications of immunologic phenotyping in cutaneous T cell lymphoma.Journal of the American Academy of Dermatology, 17 1
J. Quesada, J. Gutterman, E. Hersh (1986)
Treatment of hairy cell leukemia with alpha interferonsCancer, 57
Herberman Rb, Oldham Rk (1983)
Cell-mediated cytotoxicity against human tumors: lessons learned and future prospects.Journal of biological response modifiers, 2 2
Kempf RA Hengst JCD (1983)
Immunological effects of recombinant interferon alpha2 in cancer patientsJ Biol Response Mod, 2
J. Wolff, J. Zitelli, B. Rabin, K. Smiles, E. Abell (1985)
Intralesional interferon in the treatment of early mycosis fungoides.Journal of the American Academy of Dermatology, 13 4
P. Bunn, K. Foon, D. Ihde, D. Longo, J. Eddy, C. Winkler, S. Veach, J. Zeffren, S. Sherwin, R. Oldham (1984)
Recombinant leukocyte A interferon: an active agent in advanced cutaneous T-cell lymphomas.Annals of internal medicine, 101 4
R. Suhadolnik, M. Flick, J. Mosca, Y. Sawada, P. Doetsch, E. Vonderheid (1983)
2',5'-oligoadenylate synthetase from cutaneous T-cell lymphoma: biosynthesis, identification, quantitation, molecular size of the 2',5'-oligoadenylates, and inhibition of protein synthesis.Biochemistry, 22 17
Herberman Rb, Thurman Gb (1983)
Approaches to the immunological monitoring of cancer patients treated with natural or recombinant interferons.Journal of biological response modifiers, 2
P. Bunn, D. Ihde, K. Foon (1986)
The role of recombinant interferon alfa‐2a in the therapy of cutaneous t‐cell lymphomasCancer, 57
J. Gutterman, G. Blumenschein, R. Alexanian, H. Yap, A. Buzdar, F. Cabanillas, G. Hortobagyi, E. Hersh, S. Rasmussen, M. Harmon, M. Kramer, S. Pestka (1980)
Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma.Annals of internal medicine, 93 3
R. Spiegel, J. Spicehandler, S. Jacobs, E. Oden (1986)
Low incidence of serum neutralizing factors in patients receiving recombinant alfa-2b interferon (Intron A).The American journal of medicine, 80 2
E. Stiehm, L. Kronenberg, H. Rosenblatt, Y. Bryson, T. Merigan (1982)
Interferon: Immunobiology and Clinical SignificanceAnnals of Internal Medicine, 96
M. Onsrud (1982)
Enhancement of suppressor cell generation in human mixed lymphocyte cultures by interferon.International archives of allergy and applied immunology, 67 4
B. Baker, A. Swain, L. Fry, H. Valdimarsson (1984)
Epidermal T lymphocytes and HLA‐DR expression in psoriasisBritish Journal of Dermatology, 110
Abstract • A two-part clinical trial was conducted to determine the therapeutic efficacy of recombinant interferon alfa-2b in plaque-phase mycosis fungoides. In an initial randomized double-blind study, each of six patients had two representative plaques injected intralesionally with 1 × 106 U of recombinant interferon alfa-2b per site and two control plaques injected with placebo three times weekly for four consecutive weeks. Complete clinical regression of disease was observed at ten of 12 recombinant interferon alfa-2b sites compared with one of 12 placebo-treated sites four weeks after treatment with injections was stopped. Subsequently, in an open-labeled study, five of these patients were treated intramuscularly with 5 × 106 U of recombinant interferon alfa-2b three times weekly for four weeks and two patients were treated with a second, more extended course of therapy lasting 12 to 16 weeks. Three of the five patients treated systemically showed some improvement overall, but the responses were judged not to be clinically significant. The differential response observed from intralesional and intramuscular injections may be related to differences in concentration of recombinant interferon alfa-2b achieved in lesional skin by the two methods of administration. (Arch Dermatol 1987;123:757-763) References 1. Bunn PA Jr, Foon KA, Ihde DC, et al: Recombinant leukocyte A interferon: An active agent in advanced cutaneous T-cell lymphomas . Ann Intern Med 1984;101:484-487.Crossref 2. Bunn PA Jr, Ihde DC, Foon KA: The role of recombinant interferon alfa-2a in the therapy of cutaneous T-cell lymphomas . Cancer 1986;57:1689-1695.Crossref 3. Wolff JM, Zitelli JA, Rabin BS, et al: Intralesional interferon in the treatment of early mycosis fungoides . J Am Acad Dermatol 1985;13:601-612.Crossref 4. Spiegel RJ, Spicehandler JR, Jacobs SL, et al: Low incidence of serum neutralizing factors in patients receiving recombinant alfa-2b interferon (Intron A) . Am J Med 1986;80:223-228.Crossref 5. Bunn PA Jr, Lamberg SI: Report of the committee on staging and classification of cutaneous T-cell lymphomas . Cancer Treat Rep 1979;63;725-728. 6. Steihm ER, Kronenberg LH, Rosenblatt HM, et al: Interferon: Immunobiology and clinical significance . Ann Intern Med 1982;96:80-93.Crossref 7. Foon KA, Sherwin SA, Abrams PG, et al: Treatment of advanced non-Hodgkins lymphoma with recombinant leukocyte A interferon . N Engl J Med 1984;311:1148-1152.Crossref 8. Gutterman JU, Blumenschein GR, Alexanian R, et al: Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma . Ann Intern Med 1980;93:399-406.Crossref 9. Quesada JR, Gutterman JU, Hersch EM: Treatment of hairy cell leukemia with alpha interferons . Cancer 1986;57:1678-1680.Crossref 10. Ohno R, Kimura K: Treatment of multiple myeloma with recombinant interferon alfa-2a . Cancer 1986;57:1685-1688.Crossref 11. Borden EC: Interferons: Rationale for clinical trials in neoplastic disease . Ann Intern Med 1979;91:472-479.Crossref 12. Herberman RB, Oldham RK: Cell-mediated cytotoxicity against human tumors: Lessons learned and future prospects . J Biol Response Mod 1983;2:111-120. 13. Herberman RB, Thurman GB: Approaches to the immunological monitoring of cancer patients treated with natural or recombinant interferons . J Biol Response Mod 1983;2:548-562. 14. Ozer H, Gavigan M, O'Malley J, et al: Immunomodulation by recombinant interferon-alpha2 in a phase I trial in patients with lymphoproliferative malignancies . J Biol Response Mod 1983; 2:499-515. 15. Hengst JCD, Kempf RA, Kan-Mitchell J, et al: Immunological effects of recombinant interferon alpha2 in cancer patients . J Biol Response Mod 1983;2:516-527. 16. Suhadolnik RJ, Flick MB, Mosca JD, et al: 2′,5′-Oligoadeny-igoadenylate synthetase from cutaneous T-cell lymphoma: Biosynthesis, identification, quantitation, molecular size of the 2′,5′-oligoadenylates, and inhibition of protein synthesis . Biochemistry 1983; 22:4153-4158.Crossref 17. Rattner AC, Waldorf DS, Van Scott EJ: Alterations of lesions on mycosis fungoides lymphoma by direct imposition of delayed hypersensitivity reactions . Cancer 1968;21:83-88.Crossref 18. Baker BS, Swain AF, Fry L, et al: Epidermal T lymphocytes and HLA-DR expression in psoriasis . Br J Dermatol 1984;110:555-564.Crossref 19. De Panfilis G, Manara G, Ferrari C, et al: Imbalance in phenotypic expression of T cell subpopulations during different evolutional stages of lichen planus lesions . Acta Derm Venereol 1983;63:369-375. 20. Vonderheid EC, Tan E, Sobel EL, et al: Clinical implications of immunologic phenotyping in cutaneous T-cell lymphoma . J Am Acad Dermatol , in press. 21. Turbitt ML, Mackie RM: An assessment of the diagnostic value of the monoclonal antibodies Leu 8, OKT9, OKT10 and Ki67 in cutaneous lymphocytic infiltrates . Br J Dermatol 1986;115:151-158.Crossref 22. Onsrud M: Enhancement of suppressor cell generation in human mixed lymphocyte cultures by interferon . Int Arch Allergy Appl Immunol 1985;67:315-321.Crossref
Archives of Dermatology – American Medical Association
Published: Jun 1, 1987
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.